Akeso Inc Ordinary Shares AKESF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $6.40
- Day Range
- $6.32–6.32
- 52-Week Range
- $5.00–6.45
- Bid/Ask
- $6.00 / $6.52
- Market Cap
- $5.47 Bil
- Volume/Avg
- 25,154 / 33,557
Key Statistics
- Price/Earnings (Normalized)
- 19.49
- Price/Sales
- 8.28
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Akeso Inc is an investment holding company. The Company’s subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Core
- Total Number of Employees
- 2,778
- Website
- https://www.akesobio.com
Comparables
Valuation
|
Metric
|
AKESF
|
09969
|
06628
|
|---|---|---|---|
Price/Earnings (Normalized) | 19.49 | — | — |
Price/Book Value | 8.11 | 1.25 | 0.79 |
Price/Sales | 8.28 | 11.05 | 12.36 |
Price/Cash Flow | 19.45 | — | — |
Price/Earnings
AKESF
09969
06628
Financial Strength
|
Metric
|
AKESF
|
09969
|
06628
|
|---|---|---|---|
Quick Ratio | 4.36 | 4.18 | 1.50 |
Current Ratio | 4.71 | 4.42 | 1.61 |
Interest Coverage | 21.95 | — | −33.53 |
Quick Ratio
AKESF
09969
06628
Profitability
|
Metric
|
AKESF
|
09969
|
06628
|
|---|---|---|---|
Return on Assets (Normalized) | 22.72% | −4.85% | −22.79% |
Return on Equity (Normalized) | 42.96% | −6.85% | −38.31% |
Return on Invested Capital (Normalized) | 27.05% | −7.70% | −26.22% |
Return on Assets
AKESF
09969
06628
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Spwmfrzxy | Fqy | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sxxlywqk | Pbdlfyk | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Sfjvjrtr | Kfkdcf | $103.7 Bil | |
MRNA
| Moderna Inc | Sxbmqvmyr | Fgvh | $47.9 Bil | |
ARGX
| argenx SE ADR | Nzlldrnnr | Qkhz | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Xblcqvgb | Yqcj | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ytrtssdj | Vhcsk | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lrcfzmm | Wvzyzr | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cfdrczcxxt | Rmkjwjv | $12.8 Bil | |
INCY
| Incyte Corp | Pvzjvyjh | Nmtgycw | $12.1 Bil |